SA-15-P

Pricing Availability   Qty
Description: Dual inhibitor of LAG3 interaction with both MHCII and FGL1
Chemical Name: N-[4-[2-[2,5-Dimethyl-1-(phenylmethyl)-1H-pyrrol-3-yl]-2-oxoethoxy]phenyl]-2-furancarboxamide
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews
Literature (1)

Biological Activity for SA-15-P

SA-15-P is a dual inhibitor of the interaction of lymphocyte activation gene 3 (LAG3) with both the major histocompatibility complex class II (MHCII) and fibrinogen-like protein 1 (FGL1) (IC50 values from TR-FRET assay are 4.2 μM and 6.5 μM respectively).

Technical Data for SA-15-P

M. Wt 428.49
Formula C26H24N2O4
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 852846-00-5
PubChem ID 4786555
InChI Key IYGLJCOGIQDUAE-UHFFFAOYSA-N
Smiles O=C(C1=CC=CO1)NC2=CC=C(C=C2)OCC(C3=C(C)N(CC4=CC=CC=C4)C(C)=C3)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for SA-15-P

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 42.85 100

Preparing Stock Solutions for SA-15-P

The following data is based on the product molecular weight 428.49. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.33 mL 11.67 mL 23.34 mL
5 mM 0.47 mL 2.33 mL 4.67 mL
10 mM 0.23 mL 1.17 mL 2.33 mL
50 mM 0.05 mL 0.23 mL 0.47 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

References for SA-15-P

References are publications that support the biological activity of the product.

Abdel-Rahman et al (2023) Discovery of first-in-class small molecule inhibitors of lymphocyte activation gene 3 (LAG-3). ACS Med.Chem.Lett. 14 629 PMID: 37197466


If you know of a relevant reference for SA-15-P, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Immune Checkpoint Inhibitors

Keywords: SA-15-P, SA-15-P supplier, SA15P, LAG3, inhibitor, interaction, MHCII, major, histocompatibility, complex, fibrinogen, like, protein, 1, FGL1, lymphocyte, activation, gene, immune, checkpoint, Immune, Checkpoints, 8050, Tocris Bioscience

Citations for SA-15-P

Citations are publications that use Tocris products.

Currently there are no citations for SA-15-P. Do you know of a great paper that uses SA-15-P from Tocris? Please let us know.

Reviews for SA-15-P

There are currently no reviews for this product. Be the first to review SA-15-P and earn rewards!

Have you used SA-15-P?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer Metabolism Poster

Cancer Metabolism Poster

This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.